Surgery Trials

1. Comparison of Different Types of Surgery in Treating Patients With Stage IA Non-Small Cell Lung Cancer

      ClinicalTrials.gov Identifier:             NCT00499330      

This study is active, but is not recruiting participants
 
RATIONALE: Wedge resection or segmentectomy may be less invasive types of surgery than lobectomy for non-small cell lung cancer and may have fewer side effects and improve recovery. It is not yet known whether wedge resection or segmentectomy are more effective than lobectomy in treating stage IA non-small cell lung cancer.
The study will compare the Disease Free Survival in the 2 groups.
 
Ontario 
St. Joseph's Hospital, Charlton Campus, Hamilton
London Regional Cancer Center, London
Princess Margaret Hospital, Toronto
Ottawa Regional Cancer Center, Ottawa
 
Quebec 
Hopital Notre-Dame du CHUM, Montreal
CHUS-Hopital Fleurimont, Sherbrooke
L'Hopital Laval, Laval
 
British Columbia 
Surrey Memorial Hospital, Surrey
 
2. Robotic Lobectomy vs. Thoracoscopic Lobectomy for Early Stage Lung Cancer
 
      ClinicalTrials.gov Identifier:              NCT02617186      

This study is currently recruiting participants
 
Robotic lobectomy has been shown, on the basis of non-randomized studies, to have superior outcomes to thoracotomy and Thoracoscopic lobectomy. Despite the potential benefits of robotic technology, there are two major barriers against its widespread adoption in thoracic surgery. The first barrier is the lack of high-quality prospective data. To our knowledge, there are no prospective trials comparing Thoracoscopic Lobectomy to Robotic Lobectomy for early stage lung cancer. The second major barrier to the widespread adoption of robotic technology in thoracic surgery is the perceived higher cost of Robotic lobectomy. To address these barriers, the investigators will undertake the first randomized controlled trial comparing Thoracoscopic Lobectomy to Robotic Lobectomy for early stage lung cancer.
 
Prospective randomization will eliminate the biases of retrospective data and will serve to determine whether there exist any advantages to HRQOL or patient outcomes in favour of Robotic Lobectomy over Thoracoscopic Lobectomy. Furthermore, through a prospective cost-utility analysis, this trial will provide the highest quality data to evaluate the true economic impact of robotic technology in thoracic surgery.
 
Ontario 
St Joseph’s Healthcare, Hamilton
Toronto General Hospital, Toronto 

4. Evaluation of IRDye800CW-nimotuzumab in Lung Cancer Surgery

      ClinicalTrials.gov Identifier:              NCT04459065      

This study is currently recruiting participants
 
The purpose of this study is to determine the safety, optimal dose and imaging time of the investigational product, IRDye800CW-nimotuzumab for use as a near infrared imaging probe for image-guided surgery during lung cancer resection. IRDye800CW-nimotuzumab targets cancer cells over-expressing EGFR, allowing tumors to be visualized and may help surgeons better identify cancer during surgery
 
Saskatchewan
St. Paul’s Hospital, Saskatoon

5. Near-Infrared Fluorescence Guided Robotic Pulmonary Segmentectomy for Early Stage Lung Cancer

      ClinicalTrials.gov Identifier:              NCT02570815      

This study is currently recruiting participants
 
Near-Infrared Fluorescence (NIF) using indocyanine green (ICG) fluorescent dye is a recent advancement in the robotic platform of robotic surgery. The surgeon will view the CT scan to determine which segment the tumour is located in. Once identified, the surgeon will isolate the segment by cutting off the blood supply to that segment. Then ICG will be injected into a vein. It is expected that the entire lung, except the isolated segment, which will remain 'dark' as it was isolated from blood supply, will fluoresce, giving off a green hue when viewed with the da Vinci Firefly camera. The surgeon will identify 'dark' segment, and will remove it. A pathologist will examine the excised tissue to ensure that the tumour was removed in its entirety. Once confirmed, the surgeon will end the procedure. If the pathologist determines that the segment removed did not contain the entire tumour, then the surgeon will perform a routine lobectomy. This ensures patient safety and confirms that all participants will have the entire tumour removed from their lung
 
Ontario
St. Joseph’s Healthcare, Hamilton
Toronto General Hospital, Toronto
 

5. Cervical Video Assisted Thoracoscopic Surgery (C-VATS) (CT0030)

      ClinicalTrials.gov Identifier:              NCT01440244      

This study is currently recruiting participants
 
Although thoracic NOTES may not be ready for human trials, a new minimally invasive technique to access the pleural cavity and perform pleural, pulmonary and mediastinal procedures would be possible. Cervical Video Assisted Thoracoscopic Surgery (C-VATS) is a technique that borrows from traditional VATS procedures, from cervical mediastinoscopy, and from flexible endoscopy. All of these procedures are very familiar to the thoracic surgeon.
 
The current feasibility and safety study examines C-VATS as a method of evaluating, biopsying and performing pleurodesis in patients with pleural disease and or effusion.
 
Quebec 
Centre Hospitalier de l'Université de Montréal
Montréal,  H2L 4M1
 

6. Surgery Versus Stereotactic Body Radiation Therapy for Stage up to IA2 (T1a or T1b) Non-small Cell Lung Cancer (RAXSIA)

      ClinicalTrials.gov Identifier:              NCT03431415    

This study is currently recruiting participants
 
Patients with early stage lung cancer, that can undergo surgical treatment will be offered SBRT, and in conjunction with the pulmonologist will decide which treatment they prefer. We intend to complete the recruitment of patients within 02 years, then follow-up for 5 more years to collect data.
 
Quebec
Hôtel-Dieu de Québec (CHUQ)
Institut Universitaire de Cardiologie et de Pneumologie de Quebec - Université Laval